More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$8.85B
EPS
7.36
P/E ratio
41.6
Price to sales
22.28
Dividend yield
--
Beta
0.559296
Previous close
$297.90
Today's open
$299
Day's range
$295.06 - $299.88
52 week range
$202.99 - $382.54
show more
CEO
Krish S. Krishnan
Employees
295
Headquarters
Pittsburgh, PA
Exchange
Nasdaq Global Select
Shares outstanding
29633472
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Krystal Biotech, Inc. - KRYS
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Krystal Biotech, Inc. (“Krystal Biotech” or the “Company”) (NASDAQ: KRYS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire • 20 hours ago

Krystal Biotech to Present at Upcoming Investor Conferences
PITTSBURGH, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that management will take part in fireside chats and host investor meetings at the following conferences: Jefferies Global Healthcare Conference in London November 17, 2026 in London, England Fireside chat scheduled for 8:00 am GMT 9 th Annual Evercore Healthcare Conference December 1, 2026 in Coral Gables, Florida Fireside chat scheduled for 2:10 pm ET Citi's 2026 Global Healthcare Conference December 2, 2026 in Miami, Florida Fireside chat scheduled for 10:20 am ET Each presentation will be webcast live and may be accessed through a link on the Investors section of the Company's website . Archived versions of the webcasts will also be available on the Investors section of the Company's website for at least 30 days.
GlobeNewsWire • Nov 10, 2026

Krystal Biotech Q3 Earnings Call Highlights
Krystal Biotech NASDAQ: KRYS reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in the United States and international markets, while also outlining updated timelines for several clinical programs and authorizing a share repurchase program of up to $400 million.
MarketBeat • Nov 2, 2026

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 2, 2026

Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndrome Strong balance sheet, ending the quarter with $1.2 billion in cash and investments Board authorizes share repurchase program of up to $400 million PITTSBURGH, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the third quarter ended September 30, 2026 and provided a business update. “Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline,” said Krish S.
GlobeNewsWire • Nov 2, 2026

Krystal Biotech Analyst Says Stock Weakness 'Overblown'
Krystal Biotech Inc. (NASDAQ:KRYS) stock is trading lower on Monday after the company provided a third-quarter update.
Benzinga • Nov 2, 2026

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $2.66 per share a year ago.
Zacks Investment Research • Nov 2, 2026

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 26, 2026

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update.
GlobeNewsWire • Oct 22, 2026

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
Zacks Investment Research • Oct 16, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Krystal Biotech Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.